Aprea Therapeutics, Inc. (APRE) Financial Statements (2025 and earlier)

Company Profile

Business Address 3805 OLD EASTON ROAD
DOYLESTOWN, PA 18902
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22,849,88521,606,82028,786,64753,076,05289,017,686130,088,869
Cash and cash equivalent22,849,88521,606,82028,786,64753,076,05289,017,686130,088,869
Other undisclosed current assets726,254914,2751,366,8593,508,3583,399,0192,955,878
Total current assets:23,576,13922,521,09530,153,50656,584,41092,416,705133,044,747
Noncurrent Assets
Operating lease, right-of-use asset    185,811320,616521,392
Property, plant and equipment81,52288,3622,32123,87038,51541,639
Restricted cash and investments40,17040,717    
Other noncurrent assets281,662  29,37229,383107
Total noncurrent assets:403,354129,0792,321239,053388,514563,138
TOTAL ASSETS:23,979,49322,650,17430,155,82756,823,46392,805,219133,607,885
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,117,0003,000,0562,512,2283,621,6536,916,5543,827,094
Employee-related liabilities1,418,3091,515,312961,790
Accounts payable1,352,2401,670,369842,7541,773,0324,503,6192,176,852
Accrued liabilities764,7601,329,6871,669,474430,312897,623688,452
Deferred revenue  528,974    
Debt      242,329
Other undisclosed current liabilities1,243,975856,575688,8583,694,8468,414,6114,992,311
Total current liabilities:3,360,9754,385,6053,201,0867,316,49915,331,1659,061,734
Noncurrent Liabilities
Long-term debt and lease obligation:     78,847302,621
Liabilities, other than long-term debt100,000100,000    
Liability for uncertainty in income taxes100,000100,000    
Operating lease, liability     78,847302,621
Other undisclosed noncurrent liabilities     (78,847) 
Total noncurrent liabilities:100,000100,000  78,847302,621
Total liabilities:3,460,9754,485,6053,201,0867,316,49915,410,0129,364,355
Equity
Equity, attributable to parent19,307,45516,953,50625,643,67849,506,96477,395,207124,243,530
Common stock5,4813,7362,65521,85921,18721,023
Additional paid in capital350,971,225335,644,204330,060,836240,978,439231,418,356226,284,548
Accumulated other comprehensive loss(10,627,379)(10,611,273)(10,623,408)(10,358,956)(10,037,261)(11,533,778)
Accumulated deficit(321,041,872)(308,083,161)(293,796,405)(181,134,378)(144,007,075)(90,528,263)
Other undisclosed equity   1,311,063   
Total equity:19,307,45516,953,50626,954,74149,506,96477,395,207124,243,530
Other undisclosed liabilities and equity1,211,0631,211,063    
TOTAL LIABILITIES AND EQUITY:23,979,49322,650,17430,155,82756,823,46392,805,219133,607,885

Income Statement (P&L) (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(15,822,236)(16,055,194)(113,392,228)(37,446,353)(52,811,212)(29,544,298)
Other undisclosed operating income1,502,581583,231    
Operating loss:(14,319,655)(15,471,963)(113,392,228)(37,446,353)(52,811,212)(29,544,298)
Nonoperating income (expense)1,360,9441,185,207730,201636,452(1,557,852)1,484,491
Gain (loss), foreign currency transaction, before tax   317,402(890,252) 
Other nonoperating income (expense)1,360,9441,185,207730,201319,050(667,600)1,484,491
Loss from continuing operations:(12,958,711)(14,286,756)(112,662,027)(36,809,901)(54,369,064)(28,059,807)
Loss before gain (loss) on sale of properties:(36,809,901)(54,369,064)(28,059,807)
Other undisclosed net income (loss)   (317,402)890,252 
Net loss:(12,958,711)(14,286,756)(112,662,027)(37,127,303)(53,478,812)(28,059,807)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(12,958,711)(14,286,756)(112,662,027)(37,127,303)(53,478,812)(28,059,807)

Comprehensive Income (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(12,958,711)(14,286,756)(112,662,027)(37,127,303)(53,478,812)(28,059,807)
Comprehensive loss:(12,958,711)(14,286,756)(112,662,027)(37,127,303)(53,478,812)(28,059,807)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(16,106)12,135(264,452)(321,695)1,496,517(2,772,453)
Comprehensive loss, net of tax, attributable to parent:(12,974,817)(14,274,621)(112,926,479)(37,448,998)(51,982,295)(30,832,260)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: